Respiratory backup

Respiratory conditions are prevalent in various forms, which is why delivery methods take on almost as much importance as the drug being used. Issues with delivery and convenience contribute to the reality that many individuals still have poor control of their conditions and continue to live with the symptoms and risks associated with poorly managed respiratory conditions.

Glenmark has four respiratory candidates across the disease spectrum and devices. This includes our most advanced respiratory candidate Ryaltris™ (olopatadine hydrochloride (665 mcg) and mometasone furoate (25 mcg)), formerly GSP 301 nasal spray, which is a combination steroid-antihistamine nasal spray being investigated as a treatment for seasonal allergic rhinitis (SAR) in patients 12 years of age and older. “Ryaltris (olopatadine hydrochloride (665 mcg) and mometasone furoate (25 mcg))” has been conditionally accepted by the U.S. Food & Drug Administration (FDA) as the brand name. Glenmark submitted its first New Drug Application (NDA) to the FDA for Ryaltris in May 2018. Glenmark’s respiratory pipeline also includes GSP 304, which is a long-acting muscarinic receptor agonist being investigated as a nebulized treatment for COPD; GBR 310, which is a biosimilar for omalizumab being developed as a treatment for asthma and chronic idiopathic urticaria (hives); and GRC 39815, which is being investigated preclinically for the treatment of COPD.

Click here to view our innovative pipeline.

For more information about patient resources, please visit:
The American Thoracic Society
The Asthma and Allergy Foundation

12 million adults
in the US are diagnosed with
Chronic Obstructive
Pulmonary Disease (COPD),
and 120,000 die from it each year.

Asthma affects
1 in every 12
Americans or 8 percent of the
US population.

Nearly 1 in 5 individuals will
experience an episode of
Chronic Idiopathic Urticaria
in their lifetime.

More than
23 million American
adults and children are affected
by seasonal allergic rhinitis.